In a move that may spark another tussle with the pharmaceutical industry, the Chilean health minister has endorsed the idea of allowing the government to grant compulsory licenses for hepatitis C treatments, a step that was actively sought by lawmakers and patient advocates.

This comes in response to concern over rising prices, an issue that has prompted other cash-strapped governments to consider licenses in order to cover escalating costs. In Chile, the market price for Sovaldi, a Gilead Sciences (GILD) medicine that was the first in a new generation of treatments, is about $36,000 per patient, according to patient advocates.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • In Italy patients are allowed to purchase Sofosbuvir tablets For personal use only (not For resale) from abroad at far cheaper prices.In India thé price per box is less than $300 (you need 3 boxes For a treatment). Thé product is manufactured in India under a licence of thé patent holder.It is also manufactured in other countries.It would seem That, in Egypt, The industrial cost of a full treatment is around $280!!!!!! Hands.Vico

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy